iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier.
iCAD, a provider of advanced image analysis and workflow solutions to identify cancer, is seeking 510(k) clearance from the FDA for its VeraLook computer-aided detection (CAD) for CT colonography (CTC), or virtual colonoscopy on May 26th 2009.
The expected date for FDA decision in 1st Qtr 2010.
ICAD has been trading at $1.55 as of today, the average price for last 1 month is $1.50.
Target Price: $ 3.00 for January 2010.
You can find more news on ICAD at
http://www.icadmed.com/newsevents/content_landing1-2009.html
http://www.google.com/finance?q=NASDAQ%3AICAD
No comments:
Post a Comment